TW239869B - - Google Patents
Download PDFInfo
- Publication number
- TW239869B TW239869B TW081105670A TW81105670A TW239869B TW 239869 B TW239869 B TW 239869B TW 081105670 A TW081105670 A TW 081105670A TW 81105670 A TW81105670 A TW 81105670A TW 239869 B TW239869 B TW 239869B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- annexin
- conjugate
- item
- patent application
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3153—Streptokinase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4721—Lipocortins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69736491A | 1991-05-09 | 1991-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW239869B true TW239869B (de) | 1995-02-01 |
Family
ID=24800848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW081105670A TW239869B (de) | 1991-05-09 | 1992-07-17 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0538459A4 (de) |
JP (1) | JPH05508664A (de) |
CA (1) | CA2086437A1 (de) |
TW (1) | TW239869B (de) |
WO (1) | WO1992019279A1 (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE254631T1 (de) * | 1993-12-07 | 2003-12-15 | Neorx Corp | Pretargeting verfahren und mitteln |
ATE237366T1 (de) * | 1994-01-24 | 2003-05-15 | Neorx Corp | Radioaktiv-markierte annexine |
US5968477A (en) * | 1994-01-24 | 1999-10-19 | Neorx Corporation | Radiolabeled annexin conjugates with hexose and a chelator |
EP0765166B1 (de) * | 1994-06-16 | 2003-05-21 | Neorx Corporation | Radioaktivmarkierte annexin-galaktose konjugate |
ATE240749T1 (de) * | 1994-06-16 | 2003-06-15 | Neorx Corp | Radioaktivmarkierte annexin-galaktose konjugate |
CA2206274C (en) * | 1994-12-07 | 2009-06-30 | Neorx Corporation | Radiolabeled annexin-galactose cluster conjugates |
JPH10512852A (ja) * | 1994-12-07 | 1998-12-08 | ネオルクス コーポレイション | 放射性標識化アネキシン−ガラクトースクラスター複合体 |
AU754577B2 (en) | 1997-04-30 | 2002-11-21 | Board Of Trustees Of The Leland Stanford Junior University | Method of imaging cell death in vivo |
US6511829B1 (en) * | 1997-10-09 | 2003-01-28 | The Regents Of The University Of California | GFP-annexin fusion proteins |
FR2784106B1 (fr) * | 1998-10-02 | 2002-04-19 | Commissariat Energie Atomique | Structure chimique ayant une affinite pour un phospholipide, et compose de marquage, trousse de diagnostic, et medicament comprenant cette structure |
DE60219611T2 (de) * | 2001-02-21 | 2007-12-27 | Alavita Pharmaceuticals, Inc., Mountain View | Modifizierte annexin-proteine und verhinderung und behandlung von thrombose |
US7645739B2 (en) | 2001-02-21 | 2010-01-12 | Alavita Pharmaceuticals, Inc. | Modified annexin compositions and methods of using same |
US7635680B2 (en) | 2001-02-21 | 2009-12-22 | Alavita Pharmaceuticals, Inc. | Attenuation of reperfusion injury |
US7635676B2 (en) | 2001-02-21 | 2009-12-22 | Alavita Pharmaccuticals, Inc. | Modified annexin proteins and methods for their use in organ transplantation |
EP1372740A2 (de) | 2001-04-03 | 2004-01-02 | Theseus Imaging Corporation | Verfahren zur verwendung von annexin zum nachweis des zelltods in vivo und zur behandlung relevanter erkrankungen |
JP2004529922A (ja) | 2001-04-03 | 2004-09-30 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | 生体内における細胞死の画像化の方法 |
FR2841557B1 (fr) * | 2002-07-01 | 2005-12-09 | Commissariat Energie Atomique | Peptides ayant une affinite pour un phospholipide et utilisations |
FR2841558B1 (fr) * | 2002-07-01 | 2004-08-13 | Commissariat Energie Atomique | Peptides marques ayant une affinite pour un phospholipide et utilisations |
FR2856069A1 (fr) * | 2003-06-10 | 2004-12-17 | Bionexis | Molecules de ciblage et de liberation de composes therapeutiques et leur utilisation |
JP7051826B2 (ja) | 2016-09-23 | 2022-04-11 | シーエスエル、リミテッド | 凝固因子結合タンパク質及びその使用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT87083B (pt) * | 1987-03-28 | 1992-07-31 | Boehringer Ingelheim Int | Processo para a preparacao de uma proteina anticoagulante vascular, de adn que codifica para esta proteina e de composicoes farmaceuticas que a contem |
US5225537A (en) * | 1989-12-29 | 1993-07-06 | Zymogenetics, Inc. | Methods for producing hybrid phospholipid-binding proteins |
WO1992005749A1 (en) * | 1990-10-04 | 1992-04-16 | New England Deaconess Hospital Corporation | Soluble thrombogenesis inhibitor conjugates |
-
1992
- 1992-05-11 JP JP92512046A patent/JPH05508664A/ja active Pending
- 1992-05-11 EP EP19920913004 patent/EP0538459A4/en not_active Ceased
- 1992-05-11 CA CA002086437A patent/CA2086437A1/en not_active Abandoned
- 1992-05-11 WO PCT/US1992/003960 patent/WO1992019279A1/en not_active Application Discontinuation
- 1992-07-17 TW TW081105670A patent/TW239869B/zh active
Also Published As
Publication number | Publication date |
---|---|
CA2086437A1 (en) | 1992-11-10 |
EP0538459A4 (en) | 1993-06-16 |
JPH05508664A (ja) | 1993-12-02 |
EP0538459A1 (de) | 1993-04-28 |
WO1992019279A1 (en) | 1992-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW239869B (de) | ||
US5632986A (en) | Phospholipid-targeted thrombolytic agents | |
TW538048B (en) | A soluble derivative of a soluble polypeptide and its use | |
RU2466141C2 (ru) | МОДИФИЦИРОВАННЫЙ КОАГУЛИРУЮЩИЙ ФАКТОР VIIa С ПРОДЛЕННЫМ ВРЕМЕНЕМ ПОЛУЖИЗНИ | |
TW587081B (en) | Vitamin K-dependent polypeptide with enhanced membrane binding affinity, protein C or activated protein C polypeptide, and pharmaceutical composition thereof | |
US5011686A (en) | Thrombus specific conjugates | |
CN101405017A (zh) | 具有磷脂酰丝氨酸结合结构域的嵌合蛋白 | |
JPH05508766A (ja) | フィブリン結合ドメインポリペプチド及びその使用,並びにその製造方法 | |
CN104145015A (zh) | 靶向的溶酶体酶化合物 | |
US20140248686A1 (en) | Therapeutic polypeptides with increased in vivo recovery | |
MX2010010759A (es) | Mutantes de estreptocinasa y sus formas covalentemente modificadas. | |
JP2015501137A (ja) | 止血を調節するための組成物および方法 | |
JP2007528847A (ja) | 通常の細胞保護活性を有するが抗凝固活性が低下した活性化プロテインc変異体 | |
EA005944B1 (ru) | Фибринолитически активный полипептид | |
US5474766A (en) | Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator | |
JPH05506646A (ja) | ヒト・フォンビルブラント因子のクローニング及び製造、並びにその使用方法 | |
JPH10505502A (ja) | 修飾されたコラーゲン誘導血小板凝集阻害剤パリジピンの製法 | |
JPH04505554A (ja) | 可溶性トロンボモジュリン類似体 | |
WO2002014369A9 (en) | Human kininogen d5 domain polypeptides and their use | |
JP3095771B2 (ja) | ヒトフィブロネクチンポリペプチド類似体のクローニング及び製造並びにこのようなポリペプチド類似体の使用法 | |
US20030082740A1 (en) | Histidine proline rich glycoprotein (HPRG) as an anti-angiogenic and anti-tumor agent | |
JPS63269980A (ja) | 新規化合物、その製法及びそれを含む医薬組成物 | |
WO2023275024A1 (en) | Factor ix subcutaneous administration with enhanced safety | |
EP2504027A1 (de) | Beschleunigte wundheilung durch einen gewebehemmer aus an glycosylphosphatidylinositol-anker gebundenen metalloproteinasen | |
MIRZA | jllafiter of $ l| ilofl (oplip |